Ouabain-digoxin antagonism in rat arteries and neurones

Journal of Physiology

Volumn 592, Issue 5, 2014, Pages 941-969

  Song, Hong ^a   Karashima, Eiji ^a   Hamlyn, John M ^a   Blaustein, Mordecai P ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2,5 DIFLUOROBENZYLOXY)PHENOXY] 5 ETHOXYANILINE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BUFALIN; CALCIUM ION; DIGITOXIN; DIGOXIGENIN; DIGOXIN; DIHYDROOUABAIN; FURA 2; GLUTAMIC ACID; MARINOBUFAGENIN; OUABAGENIN; OUABAIN; PROSCILLARIDIN; ROSTAFUROXIN; STROPHANTHIDIN; TRITIUM;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL PRESSURE; ARTERY DIAMETER; ARTICLE; BLOOD VESSEL REACTIVITY; CALCIUM SIGNALING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DETERMINATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; EMBRYO; EVOKED RESPONSE; FETUS; HIPPOCAMPUS; HYPERTENSION; MALE; MESENTERIC ARTERY; MUSCLE TONE; NERVE CELL; NONHUMAN; OLIGOMERIZATION; PRESSOR RESPONSE; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

ANIMALS; BLOOD FLOW VELOCITY; CALCIUM SIGNALING; CARDIOTONIC AGENTS; CELLS, CULTURED; DIGOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HIPPOCAMPUS; MALE; MESENTERIC ARTERIES; NEURONS; OUABAIN; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 84896714316     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2013.266866     Document Type: Article

References (115)

1. Abarquez RF Jr (1967). Digitalis in the treatment of hypertension. A preliminary report. Acta Med Philipp 3, 161-170.
2. Arad M, Shotan A, Heller M, Rabinowitz B & Uretzki G (1993). In vivo assessment of the inotropic and toxic effects of oxidized ouabain. Basic Res Cardiol 88, 42-51.
3. +. Am J Physiol Heart Circ Physiol 279, H679-H691.
4. +-ATPase: on the number of the ATP sites of the functional unit. J Bioenerg Biomembr 19, 359-374.
5. Bagrov AY, Shapiro JI & Fedorova OV (2009). Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol Rev 61, 9-38.
6. Baker PF, Blaustein MP, Hodgkin AL & Steinhardt RA (1969). The influence of calcium on sodium efflux in squid axons. J Physiol 200, 431-458.
7. 8 by means of small-angle X-ray scattering. J Phys Chem B 114, 11371-11376.
8. +-ATPase activity in skeletal muscle cells. J Biol Chem 287, 23451-23463.
9. Blanco G & Mercer RW (1998). Isozymes of the Na-K-ATPase: heterogeneity in structure, diversity in function. Am J Physiol Renal Physiol 275, F633-F650.
10. Blaustein MP (1977). Sodium ions, calcium ions, blood pressure regulation, and hypertension: a reassessment and a hypothesis. Am J Physiol Cell Physiol 232, C165-C173.
11. 2+ stores and responsiveness. Am J Physiol Cell Physiol 264, C1367-C1387.
12. 2+ exchanger and TRPC proteins. Biochim Biophys Acta 1082, 1219-1229.
13. Blaustein MP, Juhaszova M & Golovina VA (1998). The cellular mechanism of action of cardiotonic steroids: a new hypothesis. Clin and Exp Hypertens 20, 691-703.
14. Blaustein MP, Leenen FH, Chen L, Golovina VA, Hamlyn JM, Pallone TL, Van Huysse JW, Zhang J & Wier WG (2012). How NaCl raises blood pressure: a new paradigm for the pathogenesis of salt-dependent hypertension. Am J Physiol Heart Circ Physiol 302, H1031-H1049.
15. 4. Eur J Biochem 195, 407-419.
16. Chang Y & Cardinal JR (1978). Light-scattering studies on bile acid salts I: Pattern of self-association of sodium cholate, sodium glycocholate, and sodium taurocholate in aqueous electrolyte solutions. J Pharm Sci 67, 174-181.
17. Clarke RJ & Fan X (2011). Pumping ions. Clin Exp Pharmacol Physiol 38, 726-733.
18. +-ATPase: lack of a direct catecholamine-mediated stimulation in bovine myocardial tissue. J Cardiovasc Pharmacol 5, 446-449.
19. +-ATPase. Biochim Biophys Acta 1235, 205-212.
20. DeWire SM & Violin JD (2011). Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology. Circ Res 109, 205-216.
21. Digitalis Investigative Group (1997). The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336, 525-533.
22. Donnet C, Arystarkhova E & Sweadner KJ (2001). Thermal denaturation of the Na, K-ATPase provides evidence for α-α oligomeric interaction and γ subunit association with the C-terminal domain. J Biol Chem 276, 7357-7365.
23. Dostanic I, Lorenz JN, Schultz Jel J, Grupp IL, Neumann JC, Wani MA & Lingrel JB (2003). The α2 isoform of Na, K-ATPase mediates ouabain-induced cardiac inotropy in mice. J Biol Chem 278, 53026-53034.
24. 2-isoform of Na-K-ATPase mediates ouabain-induced hypertension in mice and increased vascular contractility in vitro. Am J Physiol Heart Circ Physiol 288, H477-H485.
25. Dostanic-Larson I, Lorenz JN, Van Huysse JW, Neumann JC, Moseley AE & Lingrel JB (2006). The physiological role of the α1 and α2 isoforms of the Na, K-ATPase and biological significance of their cardiac glycoside binding site. Am J Physiol Regul Integr Comp Physiol 290, R524-R528.
26. Dostanic-Larson I, Van Huysse JW, Lorenz JN & Lingrel JB (2005). The highly conserved cardiac glycoside binding site of Na, K-ATPase plays a role in blood pressure regulation. Proc Natl Acad Sci U S A 102, 15845-15850.
27. 1 sodium pump, marinobufagenin, is a novel mediator of sodium chloride-dependent hypertension. Circulation 105, 1122-1127.
28. +-ATPase and cardiac steroids in the regulation of endocytosis. Am J Physiol Cell Physiol 293, C885-C896.
29. Ferrandi M, Manunta P, Rivera R, Bianchi G & Ferrari P (1998). Role of the ouabain-like factor and Na-K pump in rat and human genetic hypertension. Clin Exp Hypertens 20, 629-639.
30. Ferrari P (2010). Rostafuroxin: An ouabain-inhibitor counteracting specific forms of hypertension. Biochim Biophys Acta 1802, 1254-1258.
31. Ferrari P, Torielli L, Ferrandi M, Padoani G, Duzzi L, Florio M, Conti F, Melloni P, Vesci L, Corsico N & Bianchi G (1998). PST2238: A new antihypertensive compound that antagonizes the long-term pressor effect of ouabain. J Pharmacol Exp Ther 285, 83-94.
32. Fieser LF & Fieser M (1959). Steroids. Reinhold Publishing Corp., New York.
33. Garzelli C, Bazzichi A, Dayah AM, Manunta M, Incaprera M & Falcone G (1992). Epstein-Barr virus-transformed B lymphocytes produce low molecular mass molecules with autocrine growth factor and competence factor activity. FEMS Microbiol Lett 79, 449-454.
34. Gheorghiade M, Fonarow GC, van Veldhuisen DJ, Cleland JG, Butler J, Epstein AE, Patel K, Aban IB, Aronow WS, Anker SD & Ahmed A (2013). Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J 34, 1489-1497.
35. Gilbert DB, Tanford C & Reynolds JA (1975). Cholesterol in aqueous solution: hydrophobicity and self-association. Biochemistry (Mosc) 14, 444-448.
36. Godfraind T, Ghysel-Burton J & De Pover A (1982). Dihydroouabain is an antagonist of ouabain inotropic action. Nature 299, 824-826.
37. 2+ signaling. Am J Physiol Cell Physiol 284, C475-C486.
38. Gottlieb SS, Rogowski AC, Weinberg M, Krichten CM, Hamilton BP & Hamlyn JM (1992). Elevated concentrations of endogenous ouabain in patients with congestive heart failure. Circulation 86, 420-425.
39. Haberland ME & Reynolds JA (1973). Self-association of cholesterol in aqueous solution. Proc Natl Acad Sci U S A 70, 2313-2316.
40. +-pump ATPase in human erythrocytes. Radiation target size analyses. J Biol Chem 260, 14016-14019.
41. Hamlyn JM, Blaustein MP, Bova S, DuCharme DW, Harris DW, Mandel F, Mathews WR & Ludens JH (1991). Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci U S A 88, 6259-6263.
42. Hamlyn JM, Cohen N, Zyren J & Blaustein MP (1985). Activating effects of low dose cardiotonic steroids on dog kidney Na, K-ATPase activity: role of endogenous inhibition. In The Sodium Pump, ed. Glynn I & Ellory C, pp. 667-673. The Company of Biologists, Cambridge.
43. Hamlyn JM, Hamilton BP & Manunta P (1996). Endogenous ouabain, sodium balance and blood pressure: a review and a hypothesis. J Hypertens 14, 151-167.
44. +)ATPase associated with essential hypertension. Nature 300, 650-652.
45. Hegyvary C (1975). Covalent labeling of the digitalis-binding component of plasma membranes. Mol Pharmacol 11, 588-594.
46. Hoch JH (1961). A Survey of Cardiac Glycosides and Genins. University of South Carolina Press, Charleston, SC, USA.
47. Hougen TJ, Spicer N & Smith TW (1981). Stimulation of monovalent cation active transport by low concentrations of cardiac glycosides. Role of catecholamines. J Clin Invest 68, 1207-1214.
48. Huang BS, Kudlac M, Kumarathasan R & Leenen FH (1999). Digoxin prevents ouabain and high salt intake-induced hypertension in rats with sinoaortic denervation. Hypertension 34, 733-738.
49. 2+ exchanger type-1 in vascular smooth muscle. Nat Med 10, 1193-1199.
50. Jacobs BE, Liu Y, Pulina MV, Golovina VA & Hamlyn JM (2012). Normal pregnancy: mechanisms underlying the paradox of a ouabain-resistant state with elevated endogenous ouabain, suppressed arterial sodium calcium exchange, and low blood pressure. Am J Physiol Heart Circ Physiol 302, H1317-H1329.
51. + pump α subunit isoforms in plasmalemma. Physiological implications. Ann N Y Acad Sci 834, 524-536.
52. Kawamura A, Guo J, Itagaki Y, Bell C, Wang Y, Haupert GT Jr, Magil S, Gallagher RT, Berova N & Nakanishi K (1999). On the structure of endogenous ouabain. Proc Natl Acad Sci U S A 96, 6654-6659.
53. Kenakin TP (2012). Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Br J Pharmacol 165, 1659-1669.
54. Kirch W (2001). Pressor and vascular effects of cardiac glycosides. Eur J Clin Invest 31 (Suppl. 2), 5-9.
55. Laredo J, Hamilton BP & Hamlyn JM (1994). Ouabain is secreted by bovine adrenocortical cells. Endocrinology 135, 794-797.
56. Laredo J, Shah JR, Lu ZR, Hamilton BP & Hamlyn JM (1997). Angiotensin II stimulates secretion of endogenous ouabain from bovine adrenocortical cells via angiotensin type 2 receptors. Hypertension 29, 401-407.
57. Laughery M, Todd M & Kaplan JH (2004). Oligomerization of the Na, K-ATPase in cell membranes. J Biol Chem 279, 36339-36348.
58. Lee KS & Yu DH (1963). A study of the sodium- and potassium-activated adenosinetriphosphatase activity of heart microsomal fraction. Biochem Pharmacol 12, 1253-1264.
59. 2+ sensor. Proc Natl Acad Sci U S A 103, 13232-13237.
60. 2+ signaling in human arterial myocytes: a mechanism that links salt to increased vascular resistance? Am J Physiol Heart Circ Physiol 303, H784-794.
61. Lingrel JB (2010). The physiological significance of the cardiotonic steroid/ouabain-binding site of the Na, K-ATPase. Annu Rev Physiol 72, 395-412.
62. +-ATPase subunit. Am J Physiol Heart Circ Physiol 295, H273-H280.
63. 2+-release channels: a possible role in cardiac inotropy. Br J Pharmacol 108, 1043-1050.
64. Manunta P, Hamilton BP & Hamlyn JM (2001). Structure-activity relationships for the hypertensinogenic activity of ouabain: role of the sugar and lactone ring. Hypertension 37, 472-477.
65. Manunta P, Hamilton J, Rogowski AC, Hamilton BP & Hamlyn JM (2000). Chronic hypertension induced by ouabain but not digoxin in the rat: antihypertensive effect of digoxin and digitoxin. Hypertens Res 23 (Suppl.), S77-85.
66. Manunta P, Hamlyn JM, Simonini M, Messaggio E, Lanzani C, Bracale M, Argiolas G, Casamassima N, Brioni E, Glorioso N & Bianchi G (2011). Endogenous ouabain and the renin-angiotensin-aldosterone system: distinct effects on Na handling and blood pressure in human hypertension. J Hypertens 29, 349-356.
67. Manunta P, Tyzack J, Hamilton BP & Hamlyn JM (1993). Augmentation and antagonism of ouabain-induced hypertension. Hypertension 22, 432.
68. +-ATPase, nor do the sites coexist in native enzyme. J Biol Chem 275, 24512-24517.
69. Movitt ER (1949). Digitalis and other Cardiotonic Drugs. Oxford University Press, New York.
70. Nesher M, Shpolansky U, Viola N, Dvela M, Buzaglo N, Ben-Ami HC, Rosen H & Lichtstein D (2010). Ouabain attenuates cardiotoxicity induced by other cardiac steroids. Br J Pharmacol 160, 346-354.
71. Nishio M, Ruch SW, Kelly JE, Aistrup GL, Sheehan K & Wasserstrom JA (2004). Ouabain increases sarcoplasmic reticulum calcium release in cardiac myocytes. J Pharmacol Exp Ther 308, 1181-1190.
72. Nutikka A, Pang H, Soldin S & Lingwood C (1991). Synthesis and structural characterization of a cardioactive biotinylated digoxin analogue. Clin Biochem 24, 469-473.
73. O'Brien WJ, Lingrel JB & Wallick ET (1994). Ouabain binding kinetics of the rat alpha two and alpha three isoforms of the sodium-potassium adenosine triphosphate. Arch Biochem Biophys 310, 32-39.
74. Ogan JT, Reifenberger MS, Milanick MA & Gatto C (2007). Kinetic characterization of Na, K-ATPase inhibition by Eosin. Blood Cells Mol Dis 38, 229-237.
75. +-ATPase) with bound potassium and ouabain. Proc Natl Acad Sci U S A 106, 13742-13747.
76. Parker JC (1973). Dog red blood cells. Adjustment of salt and water content in vitro. J Gen Physiol 62, 147-156.
77. Pierdomenico SD, Bucci A, Manunta P, Rivera R, Ferrandi M, Hamlyn JM, Lapenna D, Cuccurullo F & Mezzetti A (2001). Endogenous ouabain and hemodynamic and left ventricular geometric patterns in essential hypertension. Am J Hypertens 14, 44-50.
78. 2+ entry in purinergically stimulated aorta smooth muscle cells. Circ Res 101, 1030-1038.
79. + ATPase in smooth muscle decreases blood pressure. Am J Physiol Heart Circ Physiol 293, H1172-H1182.
80. 2+ transporters in arterial smooth muscle from ouabain-induced hypertensive rats. Am J Physiol Heart Circ Physiol 298, H263-H274.
81. Puschett JB, Agunanne E & Uddin MN (2010). Marinobufagenin, resibufogenin and preeclampsia. Biochim Biophys Acta 1802, 1246-1253.
82. Quadri L, Bianchi G, Cerri A, Fedrizzi G, Ferrari P, Gobbini M, Melloni P, Sputore S & Torri M (1997). 17β-(3-furyl)-5β-Androstane-3β, 14β, 17α-triol (PST 2238). A very potent antihypertensive agent with a novel mechanism of action. J Med Chem 40, 1561-1564.
83. Raina H, Zhang Q, Rhee AY, Pallone TL & Wier WG (2010). Sympathetic nerves and endothelium influence the vasoconstrictor effect of low concentrations of ouabain in pressurized small arteries. Am J Physiol Heart Circ Physiol 298, H2093-H2101.
84. Rathore SS, Wang Y & Krumholz HM (2002). Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347, 1403-1411.
85. Repke K (1963). Influence of cardioactive principles on pump ATPase. In Proceedings of the First International Pharmacological Meeting, ed. Wilbrandt W & Lindgren P, pp. 65-73. Pergamon Press, Oxford, UK.
86. Rossi G, Manunta P, Hamlyn JM, Pavan E, De Toni R, Semplicini A & Pessina AC (1995). Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertension: relationship with plasma renin, aldosterone and blood pressure levels. J Hypertens 13, 1181-1191.
87. Schatzmann HJ (1953). [Cardiac glycosides as inhibitors of active potassium and sodium transport by erythrocyte membrane]. Helv Physiol Pharmacol Acta 11, 346-354.
88. Schneider R, Wray V, Nimtz M, Lehmann WD, Kirch U, Antolovic R & Schoner W (1998). Bovine adrenals contain, in addition to ouabain, a second inhibitor of the sodium pump. J Biol Chem 273, 784-792.
89. Schoner W & Scheiner-Bobis G (2007). Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol 293, C509-C536.
90. Segel E (1975). Enzyme Kinetics. John Wiley & Sons, New York.
91. Skriver E, Maunsbach AB, Hebert H, Scheiner-Bobis G & Schoner W (1989). Two-dimensional crystalline arrays of Na, K-ATPase with new subunit interactions induced by cobalt-tetrammine-ATP. J Ultrastruct Mol Struct Res 102, 189-195.
92. Smith TW (1986a). Basic mechanisms of cardiac glycoside action. In Digitalis Glycosides, ed. Smith TW, pp. 5-27. Grune & Stratton, Orlando.
93. Smith TW (1986b). Serum and plasma cardiac glycoside concentrations: clinical use and misuse. In Digitalis Glycosides, ed. Smith TW, pp. 153-167. Grune & Stratton, Orlando.
94. + pump α2 subunits to specialized plasma membrane microdomains. J Biol Chem 281, 12929-12940.
95. 2+ signalling in rat hippocampal neurones and glia. J Physiol 591, 1671-1689.
96. Sophocleous A, Elmatzoglou I & Souvatzoglou A (2003). Circulating endogenous digitalis-like factor(s) (EDLF) in man is derived from the adrenals and its secretion is ACTH-dependent. J Endocrinol Invest 26, 668-674.
97. Staessen JA, Thijs L, Stolarz-Skrzypek K, Bacchieri A, Barton J, Espositi ED, de Leeuw PW, Dluzniewski M, Glorioso N, Januszewicz A, Manunta P, Milyagin V, Nikitin Y, Soucek M, Lanzani C, Citterio L, Timio M, Tykarski A, Ferrari P, Valentini G, Kawecka-Jaszcz K & Bianchi G (2011). Main results of the ouabain and adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin. Trials 12, 13.
98. Strauch BS, Fales HM, Pittman RC & Avigan J (1969). Dimers and trimers of α-tocopherol: metabolic and synthetic studies. J Nutr 97, 194-202.
99. Szent-Gyorgi A (1953). Chemical Physiology of Contraction in Body and Heart Muscle. Academic Press, New York.
100. +-pump inhibitor from bovine adrenal glands. In The Sodium Pump: Structure, Mechanism, Hormonal Control and its Role in Disease, ed. Bamberg E & Schoner W, pp. 763-766. Steinkopf, Darmstadt.
101. Taniguchi K, Kaya S, Abe K & Mardh S (2001). The oligomeric nature of Na/K-transport ATPase. J Biochem 129, 335-342.
102. Tripodi G, Citterio L, Kouznetsova T, Lanzani C, Florio M, Modica R, Messaggio E, Hamlyn JM, Zagato L, Bianchi G, Staessen JA & Manunta P (2009). Steroid biosynthesis and renal excretion in human essential hypertension: association with blood pressure and endogenous ouabain. Am J Hypertens 22, 357-363.
103. + in membrane-bound and soluble protomeric αβ-units of Na, K-ATPase. J Biol Chem 262, 10511-10517.
104. 2+] transient, membrane potential, and contraction. J Gen Physiol 83, 395-415.
105. Wray S, Eisner DA & Allen DG (1985). Two hundred years of the foxglove. Med Hist Suppl, 132-150.
106. +-ATPase. J Struct Biol 174, 296-306.
107. Yoda A (1973). Structure-activity relationships of cardiotonic steroids for the inhibition of sodium- and potassium-dependent adenosine triphosphatase. I. Dissociation rate constants of various enzyme-cardiac glycoside complexes formed in the presence of magnesium and phosphate. Mol Pharmacol 9, 51-60.
108. Yoda A (1974). Association and dissociation rate constants of the complexes between various cardiac monoglycosides and Na, K-ATPase. Ann N Y Acad Sci 242, 598-616.
109. Yoda A, Yoda S & Sarrif AM (1973). Structure-activity relationships of cardiotonic steroids for the inhibition of sodium- and potassium-dependent adenosine triphosphatase. II. Association rate constants of various enzyme-cardiac glycoside complexes. Mol Pharmacol 9, 766-773.
110. Yuan CM, Manunta P, Hamlyn JM, Chen S, Bohen E, Yeun J, Haddy FJ & Pamnani MB (1993). Long-term ouabain administration produces hypertension in rats. Hypertension 22, 178-187.
111. Zhang J, Lee MY, Cavalli M, Chen L, Berra-Romani R, Balke CW, Bianchi G, Ferrari P, Hamlyn JM, Iwamoto T, Lingrel JB, Matteson DR, Wier WG & Blaustein MP (2005). Sodium pump α2 subunits control myogenic tone and blood pressure in mice. J Physiol 569, 243-256.
112. 2+ channel current, and lowers blood pressure. Am J Physiol Heart Circ Physiol 298, H1472-H1483.
113. +-induced constriction: role for SOCs in small arteries. Am J Physiol Heart Circ Physiol 283, H2692-H2705.
114. 2+ homeostasis in arterial smooth muscle cells from Milan hypertensive rats. Am J Physiol Heart Circ Physiol 299, H624-H633.
115. 2+ signaling in arterial smooth muscle cells. Am J Physiol Cell Physiol 304, C324-C333.